Galmed Pharmaceuticals
GLMD
13 hedge funds and large institutions have $3.14M invested in Galmed Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more capital invested
Capital invested by funds: $3.13M → $3.14M (+$7K)
0.04% more ownership
Funds ownership: 0% → 0.04% (+0.04%)
24% less funds holding
Funds holding: 17 → 13 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$434K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$221K |
| 3 |
Morgan Stanley
New York
|
+$118K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$69.3K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
+$43.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$73K |
| 2 |
WJA
Williams Jones & Associates
New York
|
-$67K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13.9K |
| 5 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$12.5K |
GLMD Hedge Fund Activity: Q4 2016 in Review
13 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2016, worth a combined $3.14M — up 0.22% from $3.13M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was 683 Capital Management, adding an estimated $434K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $73K sold.
- 13 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2016, down from 17 in Q3 2016.
- Funds reported $3.14M of Galmed Pharmaceuticals stock for Q4 2016, up 0.22% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q4 2016 and 5 closed out, a net change of -3 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2016 was 683 Capital Management, an estimated $434K added.
- The largest Galmed Pharmaceuticals seller in Q4 2016 was Virtu KCG Holdings, an estimated $73K sold.
Based on aggregated 13F filings for Q4 2016.